We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Palliative chemotherapy with or without cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck: Indian tertiary care retrospective analysis.
- Authors
Bahl, Ankur; Bhatia, Komal; Choudhary, Pragati; Singhla, Suhas; Shrivastava, Gunjan; Bal, Jaspriya; Anand, Anil K.; Chaturvedi, Harit; Dua, Bharat
- Abstract
Background: We report our experience with Indian patients who received palliative chemotherapy with/without cetuximab for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Methods: Data from 229 R/M SCCHN patients treated with cetuximab and chemotherapy (n = 140) or chemotherapy alone (n = 89) were retrospectively analyzed for response rate (RR), progression‐free survival (PFS), overall survival (OS), and safety. Results: Patients receiving cetuximab with chemotherapy demonstrated significant increase in RR (77.1% vs 44.9%, P =.0001), PFS (8.1 vs 6.1 months, P =.039), and OS (11.8 vs 8.0 months, P =.002) compared with patients receiving chemotherapy alone. Continuing cetuximab and changing chemotherapy combination (second line and beyond) in fit patients doubled OS (13.5 vs 6.1 months, P =.001). Adverse effects, except skin reactions (more in the cetuximab with chemotherapy group; P =.001), were similar in both groups. Conclusion: Adding cetuximab to chemotherapy improved ORR, PFS, and OS in Indian R/M SCCHN patients, and cetuximab was well tolerated.
- Subjects
SQUAMOUS cell carcinoma; TERTIARY care; COMBINATION drug therapy; CANCER chemotherapy; RETROSPECTIVE studies
- Publication
Head & Neck, 2020, Vol 42, Issue 5, p955
- ISSN
1043-3074
- Publication type
Article
- DOI
10.1002/hed.26070